Analysts Set Expectations for LFST Q1 Earnings

LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) - Equities research analysts at William Blair issued their Q1 2025 earnings per share estimates for LifeStance Health Group in a research note issued to investors on Thursday, February 27th. William Blair analyst R. Daniels forecasts that the company will earn ($0.03) per share for the quarter. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for LifeStance Health Group's current full-year earnings is ($0.18) per share. William Blair also issued estimates for LifeStance Health Group's Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.10) EPS.

A number of other research analysts have also weighed in on LFST. Barclays increased their price objective on LifeStance Health Group from $6.00 to $7.00 and gave the company an "underweight" rating in a report on Monday, November 11th. The Goldman Sachs Group raised LifeStance Health Group from a "neutral" rating to a "buy" rating and set a $10.00 price objective on the stock in a report on Monday, December 16th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, LifeStance Health Group currently has a consensus rating of "Moderate Buy" and a consensus target price of $8.70.

LifeStance Health Group Stock Performance

Shares of LFST stock traded down $0.28 during mid-day trading on Monday, reaching $7.88. The stock had a trading volume of 1,808,590 shares, compared to its average volume of 1,357,839. The business's fifty day moving average is $7.85 and its 200-day moving average is $7.28. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.19. The firm has a market cap of $3.02 billion, a price-to-earnings ratio of -30.31 and a beta of 1.28. LifeStance Health Group has a 1-year low of $4.64 and a 1-year high of $8.61.

Remove Ads

Institutional Trading of LifeStance Health Group

A number of hedge funds have recently modified their holdings of the stock. Forum Financial Management LP purchased a new stake in shares of LifeStance Health Group in the fourth quarter worth about $110,000. Neo Ivy Capital Management boosted its position in LifeStance Health Group by 26,132.3% during the fourth quarter. Neo Ivy Capital Management now owns 182,052 shares of the company's stock worth $1,341,000 after purchasing an additional 181,358 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in LifeStance Health Group by 16.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 604,321 shares of the company's stock worth $4,454,000 after purchasing an additional 87,502 shares in the last quarter. Vident Advisory LLC purchased a new position in LifeStance Health Group during the fourth quarter worth approximately $156,000. Finally, Two Sigma Advisers LP purchased a new position in LifeStance Health Group during the fourth quarter worth approximately $183,000. Hedge funds and other institutional investors own 85.50% of the company's stock.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.